{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Weinholdt C"],"funding":["Bundesministerium für Bildung und Forschung","Deutsche Forschungsgemeinschaft","Deutsche Forschungsgemeinschaft (DE)","Bundesministerium für Bildung und Forschung (DE)"],"pagination":["434"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6704634"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(1)"],"pubmed_abstract":["<h4>Background</h4>The epidermal growth factor receptor (EGFR) is a major regulator of proliferation in tumor cells. Elevated expression levels of EGFR are associated with prognosis and clinical outcomes of patients in a variety of tumor types. There are at least four splice variants of the mRNA encoding four protein isoforms of EGFR in humans, named I through IV. EGFR isoform I is the full-length protein, whereas isoforms II-IV are shorter protein isoforms. Nevertheless, all EGFR isoforms bind the epidermal growth factor (EGF). Although EGFR is an essential target of long-established and successful tumor therapeutics, the exact function and biomarker potential of alternative EGFR isoforms II-IV are unclear, motivating more in-depth analyses. Hence, we analyzed transcriptome data from glio"],"journal":["BMC bioinformatics"],"pubmed_title":["Prediction of regulatory targets of alternative isoforms of the epidermal growth factor receptor in a glioblastoma cell line."],"pmcid":["PMC6704634"],"funding_grant_id":["project number 251444481 - grant number GR 3526/6","project number 197267875 - grant number GR 3526/2","FKZ 24/19","FKZ: 16/18, 19/13, 21/25"],"pubmed_authors":["Ardell DH","Grosse I","Kappler M","Kotrba J","Vordermark D","Eckert AW","Weinholdt C","Wichmann H"],"additional_accession":[]},"is_claimable":false,"name":"Prediction of regulatory targets of alternative isoforms of the epidermal growth factor receptor in a glioblastoma cell line.","description":"<h4>Background</h4>The epidermal growth factor receptor (EGFR) is a major regulator of proliferation in tumor cells. Elevated expression levels of EGFR are associated with prognosis and clinical outcomes of patients in a variety of tumor types. There are at least four splice variants of the mRNA encoding four protein isoforms of EGFR in humans, named I through IV. EGFR isoform I is the full-length protein, whereas isoforms II-IV are shorter protein isoforms. Nevertheless, all EGFR isoforms bind the epidermal growth factor (EGF). Although EGFR is an essential target of long-established and successful tumor therapeutics, the exact function and biomarker potential of alternative EGFR isoforms II-IV are unclear, motivating more in-depth analyses. Hence, we analyzed transcriptome data from glio","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Aug","modification":"2026-05-01T04:49:13.821Z","creation":"2019-08-26T07:04:17Z"},"accession":"S-EPMC6704634","cross_references":{"pubmed":["31438847"],"doi":["10.1186/s12859-019-2944-9"]}}